Abstract Number: 3171 • ACR/ARHP Annual Meeting 2015
Combination Therapy with Denosumab and Biologic DMARD Associated with Higher Risk of Serious Infections Compared to Denosumab Alone and Biologic DMARD Alone
Background/Purpose: Patients with RA and other rheumatologic disorders are at increased risk for osteoporotic fractures. Biologic DMARDs are an important treatment option for these patients.…Abstract Number: 921 • ACR/ARHP Annual Meeting 2014
Comparison of Infection Rates in Patients Receiving Denosumab, Denosumab and Biologics and Biologics Alone in a Suburban Rheumatology Clinic
Background/Purpose: Biologics including rituximab, abatacept and belimumab increase the risk of infection in patients. Denosumab, a RANK-ligand inhibitor used in the treatment of osteoporosis may…
ACR Meeting Abstracts